CDK4 and breast carcinoma: Together, these data suggest that breast cancer cells resistant to the combination of CDK4/6i and endocrine therapy will rapidly progress on fulvestrant and AKTi, but will benefit from the addition of AKTi to the standard combination of CDK4/6i and fulvestrant.